Rapport Therapeutics (RAPP) Free Cash Flow (2023 - 2026)
Rapport Therapeutics (RAPP) reported Free Cash Flow of -$13.1 million for Q1 2026, up 35.96% year-over-year from -$9.7 million in Q1 2025, and up 47.14% quarter-over-quarter from -$24.9 million in Q4 2025.
Rapport Therapeutics (RAPP) Free Cash Flow (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Free Cash Flow data on file, last reported at -$13.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$13.1 million, up 35.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$80.7 million (down 16.84% YoY), and the FY2025 annual result was -$88.1 million, down 31.02% from the prior year.
- Free Cash Flow rose to -$13.1 million in Q1 2026 per RAPP's latest filing, from -$24.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$5.5 million in Q3 2023 and troughed at -$25.1 million in Q2 2025.
- A 4-year average of -$16.9 million and a median of -$17.3 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow plunged 202.32% in 2024, then surged 35.96% in 2026.
- A 4-year view of Free Cash Flow shows it stood at -$11.8 million in 2023, then declined by 24.4% to -$14.7 million in 2024, then plunged by 69.51% to -$24.9 million in 2025, then surged by 47.14% to -$13.1 million in 2026.
- Business Quant data shows RAPP's Free Cash Flow at -$13.1 million in Q1 2026, -$24.9 million in Q4 2025, and -$17.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | -13.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.15 Mn |
| Mar 31, 2026 | -13.15 Mn |
| Dec 31, 2025 | -24.87 Mn |
| Dec 31, 2025 | -24.87 Mn |
| Sep 30, 2025 | -17.60 Mn |
| Sep 30, 2025 | -17.60 Mn |
| Jun 30, 2025 | -25.09 Mn |
| Jun 30, 2025 | -25.09 Mn |
| Mar 31, 2025 | -20.53 Mn |
| Mar 31, 2025 | -20.53 Mn |
| Dec 31, 2024 | -14.67 Mn |
| Dec 31, 2024 | -14.67 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Jun 30, 2024 | -17.32 Mn |
| Jun 30, 2024 | -17.32 Mn |
| Mar 31, 2024 | -18.69 Mn |
| Mar 31, 2024 | -18.69 Mn |
| Dec 31, 2023 | -11.79 Mn |
| Dec 31, 2023 | -11.79 Mn |